ICER's report on VMAT2 inhibitors for tardive dyskinesia says they are 'vastly overpriced'

The US Institute for Clinical and Economic Review (ICER) has released a Final Evidence Report and Report-at-a-Glance on vesicular monoamine transporter 2 (VMAT2) inhibitors for management of tardive dyskinesia (TD), saying that the evidence suggests these drugs offer short-term benefits but are ‘vastly overpriced’.

TD is a repetitive, involuntary movement disorder caused by prolonged use of certain medications, most commonly antipsychotic drugs used to treat schizophrenia and affective disorders.

In its draft Evidence Report last month, the ICER proposed that the prices of these products should be reduced by around 90%.